Meijing Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Meijing Liu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Changhui Liu
State Key Laboratory of Traditional Chinese Medicine Syndrome, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510405, China
2 shared publications Suiqing Mi
Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China
2 shared publicationsChanghui Liu
Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Jichang Road 12, Guangzhou 510405, Guangdong Province, PR China
1 shared publicationChaozhan Lin
Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publicationChenchen Zhu
Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication- Chuangpeng Shen
State Key Laboratory of Traditional Chinese Medicine Syndrome, The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, PR China; ShenShan Hospital, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Shanwei 516600, PR China; The First People's Hospital of Kashgar Prefecture, Kashgar 844000, PR China
1 shared publication
Latest Publications
- Open Access
- 12 November 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-14
Chrysophanol Alleviates Metabolic Syndrome by Activating the SIRT6/AMPK Signaling Pathway in Brown Adipocytes
Chrysophanol, a primary active ingredient of Cassia mimosoides Linn or Rhei radix et rhizoma, has various pharmacological properties, including anticancer, antidiabetic, and anti-inflammatory, as well as blood lipid regulation. However, whether chrysophanol can mitigate obesity, and its underlying mechanisms remains unclear. This study investigated whether chrysophanol effects energy metabolism in high-fat diet- (HFD-) induced obese mice and fat-specific Sirtuin 6- (SIRT6-) knockout (FKO) mice, targeting the SIRT6/AMPK signaling pathway in brown and white fat tissue. Our results showed that chrysophanol can effectively inhibit lipid accumulation in vitro and reduce mice’s body weight, improve insulin sensitivity and reduced fat content of mice, and induce energy consumption in HFD-induced obese mice by activating the SIRT6/AMPK pathway. However, a treatment with OSS-128167, an SIRT6 inhibitor, or si-SIRT6, SIRT6 target specific small interfering RNA, in vitro blocked chrysophanol inhibition of lipid accumulation. Similar results were obtained when blocking the AMPK pathway. Moreover, in the HFD-induced obese model with SIRT6 FKO mice, histological analysis and genetic test results showed that chrysophanol treatment did not reduce lipid droplets and upregulated the uncoupling protein 1 (UCP1) expression. Rather, it upregulated the expression of thermogenic genes and activated white fat breakdown by inducing phosphorylation of adenosine 5-monophosphate- (AMP-) activated protein kinase (AMPK), both in vitro and in vivo. OSS-128167 or si-SIRT6 blocked chrysophanol’s upregulation of peroxisome proliferator-activated receptor-γ coactivator-1α (Pgc-1α) and Ucp1 expression. In conclusion, this study demonstrated that chrysophanol can activate brown fat through the SIRT6/AMPK pathway and increase energy consumption, insulin sensitivity, and heat production, thereby alleviating obesity and metabolic disorders.
- 12 November 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-14
Open AccessChrysophanol Alleviates Metabolic Syndrome by Activating the SIRT6/AMPK Signaling Pathway in Brown Adipocytes
Chrysophanol, a primary active ingredient of Cassia mimosoides Linn or Rhei radix et rhizoma, has various pharmacological properties, including anticancer, antidiabetic, and anti-inflammatory, as well as blood lipid regulation. However, whether chrysophanol can mitigate obesity, and its underlying mechanisms remains unclear. This study investigated whether chrysophanol effects energy metabolism in high-fat diet- (HFD-) induced obese mice and fat-specific Sirtuin 6- (SIRT6-) knockout (FKO) mice, targeting the SIRT6/AMPK signaling pathway in brown and white fat tissue. Our results showed that chrysophanol can effectively inhibit lipid accumulation in vitro and reduce mice’s body weight, improve insulin sensitivity and reduced fat content of mice, and induce energy consumption in HFD-induced obese mice by activating the SIRT6/AMPK pathway. However, a treatment with OSS-128167, an SIRT6 inhibitor, or si-SIRT6, SIRT6 target specific small interfering RNA, in vitro blocked chrysophanol inhibition of lipid accumulation. Similar results were obtained when blocking the AMPK pathway. Moreover, in the HFD-induced obese model with SIRT6 FKO mice, histological analysis and genetic test results showed that chrysophanol treatment did not reduce lipid droplets and upregulated the uncoupling protein 1 (UCP1) expression. Rather, it upregulated the expression of thermogenic genes and activated white fat breakdown by inducing phosphorylation of adenosine 5-monophosphate- (AMP-) activated protein kinase (AMPK), both in vitro and in vivo. OSS-128167 or si-SIRT6 blocked chrysophanol’s upregulation of peroxisome proliferator-activated receptor-γ coactivator-1α (Pgc-1α) and Ucp1 expression. In conclusion, this study demonstrated that chrysophanol can activate brown fat through the SIRT6/AMPK pathway and increase energy consumption, insulin sensitivity, and heat production, thereby alleviating obesity and metabolic disorders.
- 26 June 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (17) , 3563-3580
Activating the pregnane X receptor by imperatorin attenuates dextran sulphate sodium‐induced colitis in mice
Background and Purpose: Activation of the human pregnane X receptor (PXR; NR1I2) has potential therapeutic uses for inflammatory bowel disease (IBD). Imperatorin (IMP), a naturally occurring coumarin, is the main bioactive ingredient of Angelica dahurica Radix, which is regularly used to treat the common cold and intestinal disorders. However, there are no data on the protective effects of IMP against IBD.Experimental Approach: The effects of IMP on PXR‐modulated cytochrome P450 3A4 (CYP3A4) expression were assessed using a PXR transactivation assay, a mammalian two‐hybrid assay, a competitive ligand‐binding assay, analysis of CYP3A4 mRNA and protein expression levels and measurement of CYP3A4 activity using a cell‐based reporter gene assay and in vitro model. The inhibitory effects of IMP on NF‐κB activity were evaluated by a reporter assay and NF‐κB p65 nuclear translocation. The anti‐IBD effects of IMP were investigated in a dextran sulphate sodium (DSS)‐induced colitis mouse model. Colon inflammatory cytokines were assessed by elisa.Key Results: IMP activated CYP3A4 promoter activity, recruited steroid receptor coactivator 1 to the ligand‐binding domain of PXR and increased the expression and activity of CYP3A4. PXR knockdown substantially reduced IMP‐induced increase in CYP3A4 expression. Furthermore, IMP‐mediated PXR activation suppressed the nuclear translocation of NF‐κB and down‐regulated LPS‐induced expression of pro‐inflammatory genes. Nevertheless, PXR knockdown partially reduced the IMP‐mediated inhibition of NF‐κB. IMP ameliorated DSS‐induced colitis by PXR/NF‐κB signalling.Conclusions and Implications: IMP acts as a PXR agonist to attenuate DSS‐induced colitis by suppression of the NF‐κB‐mediated pro‐inflammatory response in a PXR/NF‐κB‐dependent manner.
- 26 June 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (17) , 3563-3580
Activating the pregnane X receptor by imperatorin attenuates dextran sulphate sodium‐induced colitis in mice
Background and Purpose: Activation of the human pregnane X receptor (PXR; NR1I2) has potential therapeutic uses for inflammatory bowel disease (IBD). Imperatorin (IMP), a naturally occurring coumarin, is the main bioactive ingredient of Angelica dahurica Radix, which is regularly used to treat the common cold and intestinal disorders. However, there are no data on the protective effects of IMP against IBD.Experimental Approach: The effects of IMP on PXR‐modulated cytochrome P450 3A4 (CYP3A4) expression were assessed using a PXR transactivation assay, a mammalian two‐hybrid assay, a competitive ligand‐binding assay, analysis of CYP3A4 mRNA and protein expression levels and measurement of CYP3A4 activity using a cell‐based reporter gene assay and in vitro model. The inhibitory effects of IMP on NF‐κB activity were evaluated by a reporter assay and NF‐κB p65 nuclear translocation. The anti‐IBD effects of IMP were investigated in a dextran sulphate sodium (DSS)‐induced colitis mouse model. Colon inflammatory cytokines were assessed by elisa.Key Results: IMP activated CYP3A4 promoter activity, recruited steroid receptor coactivator 1 to the ligand‐binding domain of PXR and increased the expression and activity of CYP3A4. PXR knockdown substantially reduced IMP‐induced increase in CYP3A4 expression. Furthermore, IMP‐mediated PXR activation suppressed the nuclear translocation of NF‐κB and down‐regulated LPS‐induced expression of pro‐inflammatory genes. Nevertheless, PXR knockdown partially reduced the IMP‐mediated inhibition of NF‐κB. IMP ameliorated DSS‐induced colitis by PXR/NF‐κB signalling.Conclusions and Implications: IMP acts as a PXR agonist to attenuate DSS‐induced colitis by suppression of the NF‐κB‐mediated pro‐inflammatory response in a PXR/NF‐κB‐dependent manner.
- 1 November 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 815, 1-9
Prevention of cholesterol gallstone disease by schaftoside in lithogenic diet-induced C57BL/6 mouse model
- 1 November 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 815, 1-9
Prevention of cholesterol gallstone disease by schaftoside in lithogenic diet-induced C57BL/6 mouse model